Proteon plans Ph III for elastase in kidney disease surgery

Proteon Therapeutics is planning to move its recombinant human elastase into Phase III trials after announcing positive results from a Phase II trial of the product, PRT-201, in chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF) in preparation for hemodialysis.